Norbert Grząśko

2.4k total citations
39 papers, 488 citations indexed

About

Norbert Grząśko is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Norbert Grząśko has authored 39 papers receiving a total of 488 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Hematology, 29 papers in Molecular Biology and 26 papers in Oncology. Recurrent topics in Norbert Grząśko's work include Multiple Myeloma Research and Treatments (32 papers), Protein Degradation and Inhibitors (18 papers) and Peptidase Inhibition and Analysis (16 papers). Norbert Grząśko is often cited by papers focused on Multiple Myeloma Research and Treatments (32 papers), Protein Degradation and Inhibitors (18 papers) and Peptidase Inhibition and Analysis (16 papers). Norbert Grząśko collaborates with scholars based in Poland, United States and Greece. Norbert Grząśko's co-authors include Marek Hus, Marta Morawska, Anna Dmoszyńska, Adam Walter‐Croneck, Catriona Byrne, W Wiktor-Jędrzejczak, Meletios Α. Dimopoulos, Andrzej Pluta, Richard Labotka and Zhaoyang Teng and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Norbert Grząśko

38 papers receiving 480 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Norbert Grząśko Poland	13	356	285	237	54	49	39	488
Xiaoying Qi China	13	311 0.9×	346 1.2×	183 0.8×	32 0.6×	86 1.8×	31	515
Daniele Derudas Italy	9	494 1.4×	369 1.3×	258 1.1×	47 0.9×	127 2.6×	30	624
Enrica Borsi Italy	12	239 0.7×	243 0.9×	157 0.7×	83 1.5×	34 0.7×	26	392
Marina Martello Italy	10	352 1.0×	303 1.1×	218 0.9×	83 1.5×	48 1.0×	30	472
Anri Tienhaara Finland	10	220 0.6×	167 0.6×	161 0.7×	27 0.5×	45 0.9×	20	412
Malathi Kandarpa United States	9	170 0.5×	335 1.2×	155 0.7×	23 0.4×	51 1.0×	44	441
Annemiek Broijl Netherlands	13	545 1.5×	463 1.6×	403 1.7×	35 0.6×	70 1.4×	50	710
Normann Steiner Austria	14	180 0.5×	219 0.8×	191 0.8×	44 0.8×	98 2.0×	55	471
Assunta Melaccio Italy	13	222 0.6×	242 0.8×	180 0.8×	94 1.7×	52 1.1×	29	473
Aurelia Lamanuzzi Italy	14	230 0.6×	309 1.1×	147 0.6×	120 2.2×	27 0.6×	19	478

Countries citing papers authored by Norbert Grząśko

Since Specialization

Citations

This map shows the geographic impact of Norbert Grząśko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norbert Grząśko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norbert Grząśko more than expected).

Fields of papers citing papers by Norbert Grząśko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Norbert Grząśko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norbert Grząśko. The network helps show where Norbert Grząśko may publish in the future.

Co-authorship network of co-authors of Norbert Grząśko

This figure shows the co-authorship network connecting the top 25 collaborators of Norbert Grząśko. A scholar is included among the top collaborators of Norbert Grząśko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Norbert Grząśko. Norbert Grząśko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Morawska, Marta, Michał Kiełbus, Agnieszka Karczmarczyk, et al.. (2024). Mutations of ARID1B, PIK3C2B, KMT2B, and FAT1 genes influence clinical outcome in newly diagnosed myeloma. Cancer Genetics. 288-289. 118–125.

Knop, Stefan, Norbert Grząśko, Karolin Trautmann‐Grill, et al.. (2024). A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma. SHILAP Revista de lepidopterología. 5(5). 940–950. 4 indexed citations

Morawska, Marta, Jadwiga Dwilewicz‐Trojaczek, Tomasz Stompór, et al.. (2023). A Stepwise Screening Protocol for Multiple Myeloma. Journal of Clinical Medicine. 12(4). 1345–1345. 1 indexed citations

Karczmarczyk, Agnieszka, et al.. (2020). Expression and Clinical Significance of Neuropilin-1 in Patients With Multiple Myeloma. Anticancer Research. 40(10). 5437–5443. 2 indexed citations

Czyż, Jarosław, et al.. (2019). 18F-fluoro-ethyl-tyrosine (18F-FET) PET/CT as a potential new diagnostic tool in multiple myeloma: a preliminary study. Współczesna Onkologia. 23(1). 23–31. 15 indexed citations

Dimopoulos, Meletios Α., Sebastian Grosicki, W Wiktor-Jędrzejczak, et al.. (2018). All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. European Journal of Cancer. 106. 89–98. 27 indexed citations

Mateos, María‐Victoria, Tamás Masszi, Norbert Grząśko, et al.. (2017). Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs . placebo-lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in TOURMALINE-MM1. Haematologica. 102(10). 1767–1775. 39 indexed citations

Kumar, Shaji, Norbert Grząśko, Sossana Delimpasi, et al.. (2017). Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 17(1). e131–e131. 9 indexed citations

Raje, Noopur, Philippe Moreau, Evangelos Terpos, et al.. (2016). Phase 2 study of tabalumab, a human anti‐B‐cell activating factor antibody, with bortezomib and dexamethasone in patients with previously treated multiple myeloma. British Journal of Haematology. 176(5). 783–795. 38 indexed citations

10.

Mateos, María‐Victoria, Tamás Masszi, Norbert Grząśko, et al.. (2016). Impact of prior therapy on efficacy and safety of oral ixazomib-lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) in TOURMALINE-MM1.. Journal of Clinical Oncology. 34(15_suppl). 8039–8039. 4 indexed citations

11.

Grząśko, Norbert, et al.. (2015). Thalidomide can promote erythropoiesis by induction of STAT5 and repression of external pathway of apoptosis resulting in increased expression of GATA-1 transcription factor. Pharmacological Reports. 67(6). 1193–1200. 2 indexed citations

12.

Dimopoulos, Meletios Α., Sebastian Grosicki, W Wiktor-Jędrzejczak, et al.. (2015). Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070). Blood. 126(23). 26–26. 13 indexed citations

13.

Grząśko, Norbert, Marta Morawska, & Marek Hus. (2014). Optimizing the Treatment of Patients With Multiple Myeloma and Renal Impairment. Clinical Lymphoma Myeloma & Leukemia. 15(4). 187–198. 23 indexed citations

14.

Morawska, Marta, et al.. (2014). Therapy‐related peripheral neuropathy in multiple myeloma patients. Hematological Oncology. 33(4). 113–119. 61 indexed citations

15.

Walter‐Croneck, Adam, et al.. (2014). A clinical comparison of the efficacy and safety of biosimilar G-CSF and originator G-CSF in haematopoietic stem cell mobilization. Pharmacological Reports. 66(2). 239–242. 24 indexed citations

16.

Hus, Marek, Norbert Grząśko, Andrzej Pluta, et al.. (2011). Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma. Annals of Hematology. 90(10). 1161–1166. 49 indexed citations

17.

Dmoszyńska, Anna, Adam Walter‐Croneck, Iwona Hus, et al.. (2010). The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma—A report by the Polish Myeloma Study Group. Leukemia Research. 34(10). 1330–1335. 11 indexed citations

18.

Kowal, Małgorzata, Marek Hus, Anna Dmoszyńska, Janusz Kocki, & Norbert Grząśko. (2008). Acute T Cell Lymphoblastic Leukemia in the Recipient of a Renal Transplant from a Donor with Malignant Lymphoma. Acta Haematologica. 119(3). 187–189. 1 indexed citations

19.

Dmoszyńska, Anna, et al.. (2006). Lovastatin and thalidomide have a combined effect on the rate of multiple myeloma cell apoptosis in short term cell cultures. European Journal of Clinical Pharmacology. 62(4). 325–329. 12 indexed citations

20.

Grząśko, Norbert. (2004). [Involvement of apoptosis and proinflammatory cytokines in the pathogenesis of anemia in multiple myeloma].. PubMed. 58. 364–71. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact